# Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer

> **NCT04593381** · NA · COMPLETED · sponsor: **Gemelli Molise Hospital** · enrollment: 376 (actual)

## Conditions studied

- Ovarian Neoplasms
- Recurrent Ovarian Carcinoma
- Oligometastatic Disease

## Interventions

- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT04593381
- **Lead sponsor:** Gemelli Molise Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2024-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04593381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04593381, "Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04593381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*